Skip to main content

Table 1 Selected characteristics of children vaccinated with BNT162b2 COVID-19 vaccine and matched unvaccinated children

From: Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study

Characteristic

Optum

CVS Health

Vaccinated with BNT162b2

N = 92,338

Matcheda Unvaccinated

N = 92,338

ASD

Vaccinated with BNT162b2

N = 361,317

Matcheda Unvaccinated

N = 361,317

ASD

Characteristics at Time 0

      

Age, years

      

 Median (Q1, Q3)

13 (9, 15)

13 (9, 15)

 

12 (9, 15)

12 (9, 15)

0.00

 Mean (SD)

12.11 (3.60)

12.08 (3.64)

0.01

11.76 (3.66)

11.71 (3.72)

0.01

Sex, N (%)

      

 Male

46,516 (50.38%)

46,516 (50.38%)

0.00

181,416 (50.21%)

181,416 (50.21%)

0.00

 Female

45,822 (49.62%)

45,822 (49.62%)

0.00

179,901 (49.79%)

179,901 (49.79%)

0.00

Region, N (%)b

      

 Northeast

13,051 (14.13%)

13,051 (14.13%)

0.00

64,684 (17.90%)

64,684 (17.90%)

0.00

 South

12,959 (14.03%)

12,959 (14.03%)

0.00

69,202 (19.15%)

69,202 (19.15%)

0.00

 Midwest

43,572 (47.19%)

43,572 (47.19%)

0.00

75,498 (20.90%)

75,498 (20.90%)

0.00

 West

22,756 (24.64%)

22,756 (24.64%)

0.00

151,933 (42.05%)

151,933 (42.05%)

0.00

Characteristics in the 365 days before Time 0, N (%)

      

Influenza vaccination

47,759 (51.72%)

47,759 (51.72%)

0.00

187,076 (51.78%)

187,076 (51.78%)

0.00

Pneumococcal vaccination

87 (0.09%)

77 (0.08%)

0.00

360 (0.10%)

368 (0.10%)

0.00

Well-check/well-child preventive healthcare visit

63,290 (68.54%)

62,515 (67.70%)

0.02

253,176 (70.07%)

246,607 (68.25%)

0.04

Characteristics assessed using all available data at or before Time 0, N (%)

      

Autoimmune disorders

1,067 (1.16%)

1,049 (1.14%)

0.00

4,273 (1.18%)

3,995 (1.11%)

0.01

Chronic lung diseases (e.g., asthma, COPD, cystic fibrosis, pulmonary embolism)

10,086 (10.92%)

10,081 (10.92%)

0.00

43,858 (12.14%)

44,283 (12.26%)

0.00

Dementia or other neurological conditions

3,110 (3.37%)

3,331 (3.61%)

0.01

12,075 (3.34%)

12,542 (3.47%)

0.01

Diabetes mellitus, type 1 or 2

436 (0.47%)

416 (0.45%)

0.00

1,480 (0.41%)

1,336 (0.37%)

0.01

Heart conditions (e.g., heart failure, coronary artery disease, arrhythmias)

3,037 (3.29%)

3,135 (3.40%)

0.01

12,537 (3.47%)

13,118 (3.63%)

0.01

Immunocompromised state

458 (0.50%)

458 (0.50%)

0.00

1,674 (0.46%)

1,674 (0.46%)

0.00

Mental health conditions

17,813 (19.29%)

16,871 (18.27%)

0.03

63,102 (17.46%)

58,900 (16.30%)

0.03

Obese or severely obese

7,750 (8.39%)

8,138 (8.81%)

0.01

35,224 (9.75%)

37,775 (10.45%)

0.02

At least one COVID-19 laboratory performed

36,002 (38.99%)

32,568 (35.27%)

0.08

174,485 (48.29%)

157,714 (43.65%)

0.09

COVID-19 diagnoses occurring outside of a hospital or emergency department

2,759 (2.99%)

2,751 (2.98%)

0.00

10,878 (3.01%)

10,812 (2.99%)

0.00

Hospitalization or emergency department–diagnosed COVID-19

116 (0.13%)

129 (0.14%)

0.00

514 (0.14%)

643 (0.18%)

0.01

  1. ASD = absolute standardized difference; COPD = Chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019; Q1, Q3 = first and third quartiles; SD = standard deviation; US = United States
  2. aMatched children on calendar date, age group, sex, US county of residence, immunocompromised status, pregnancy status, history of COVID-19 diagnosis, presence of a comorbidity identified by the Centers for Disease Control and Prevention as increasing individuals’ risk of severe COVID-19, influenza vaccination in previous year
  3. bCounty and state of residence were used for matching and propensity score models, but US census region is displayed in descriptive tables for brevity